Finance

Lists
LILY34:BVMF
Eli Lilly And Company BDR
196,79 BRL
0,00%
(0,00) 1D
9-окт., 17:06:00 GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for LILY34...
Open
195,67 BRL
High
196,79 BRL
Low
191,80 BRL
Mkt. cap
1,11 трлн
Avg. vol.
36,60 миң
Volume
41,76 миң
52-wk high
223,07 BRL
52-wk low
141,56 BRL
Shares outstanding
941,36 млн
No. of employees
50 миң
Open
195,67 BRL
High
196,79 BRL
Low
191,80 BRL
Mkt. cap
1,11 трлн
Avg. vol.
36,60 миң
Volume
41,76 миң
52-wk high
223,07 BRL
52-wk low
141,56 BRL
Shares outstanding
941,36 млн
No. of employees
50 миң
News stories
From web sources and news partners
Profile
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 90 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named. The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so. The company's primary products are tirzepatide for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea; abemaciclib for the treatment of advanced or metastatic breast cancers; dulaglutide for the treatment of type 2 diabetes; ixekizumab for the treatment of autoimmune diseases; and empagliflozin for the treatment of type 2 diabetes. Wikipedia
About Eli Lilly And Company BDR
CEODavid A. Ricks
Employees50 миң
Founded1876
HeadquartersИндианаполис, Индиана, Америка Кошмо Штаттары
SectorPharmaceutical industry
Websitelilly.com
Last report
2026-ж., 5-авг.
Fiscal period
Q2 2026
8,38 USD / 6,58 USD
+27,27%beat
Revenue / Est. (USD)
22,97 млд / 20,69 млд
+11,06%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
17,60 млд
19,29 млд
19,80 млд
22,97 млд
Cost of goods sold
3,01 млд
3,37 млд
3,58 млд
3,27 млд
Cost of revenue
3,01 млд
3,37 млд
3,58 млд
3,27 млд
Research and development expenses
3,47 млд
3,80 млд
3,51 млд
3,82 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,63 млд
3,46 млд
2,93 млд
3,43 млд
Operating expense
6,09 млд
7,26 млд
6,44 млд
7,25 млд
Total operating expenses
9,10 млд
10,63 млд
10,02 млд
10,52 млд
Operating income
8,50 млд
8,66 млд
9,78 млд
12,46 млд
Other non operating income
-9,10 млн
181,20 млн
170,00 млн
561,00 млн
EBT including unusual items
7,23 млд
8,27 млд
8,85 млд
9,25 млд
EBT excluding unusual items
8,21 млд
8,89 млд
9,71 млд
12,73 млд
Income tax expense
1,65 млд
1,63 млд
1,45 млд
2,15 млд
Effective tax rate
22,81%
19,70%
16,43%
23,27%
Other operating expenses
-
-
-
-
Net income
5,58 млд
6,64 млд
7,40 млд
7,10 млд
Net profit margin
31,72%
34,41%
37,36%
30,88%
Earnings per share
7,02
7,54
8,55
8,38
Interest and investment income
65,00 млн
672,40 млн
-
-
Interest expense
-179,60 млн
-153,30 млн
-332,00 млн
-345,00 млн
Net interest expenses
-114,60 млн
519,10 млн
-332,00 млн
-345,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
8,97 млд
9,25 млд
10,29 млд
12,99 млд
Gain or loss from assets sale
-
-180,00 млн
-
-
AI content may include mistakes. Learn more
Google колдонмолору